Acquirement
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program
Eli Lilly and Company
PR-01-25-NI-14Jan 14, 2025
Biomanufacturing
Scorpion Biological Services Becomes Scorpius BioManufacturing to Reflect Expansion
Scorpius BioManufacturing
PR-M12-22-02Dec 21, 2022
New Facility
Scorpion Biological Services Celebrates Grand Opening of its San Antonio Facility
Scorpius BioManufacturing
PR-M10-22-08Oct 27, 2022
Biodefense
Supporting Biodefense Countermeasures with Strong Capabilities and Expertise
Brian O’Mara
Scorpius BioManufacturing
PAO-09-022-CL-03Sep 19, 2022
CRDMO
Scorpion Biological Services Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer (CEO)
Scorpius BioManufacturing
PR-M06-22-03Jun 14, 2022
Bioanalytics
The Bioanalytical Development Journey
Nick Raja, Ph.D.
Scorpius BioManufacturing
PAO-05-022-CL-03May 09, 2022
New Biodefense Facility
Scorpion Biological Services Announces New Kansas Commercial Biomanufacturing Facility
Scorpius BioManufacturing
PR-M04-22-12Apr 26, 2022
New Biodefense Facility
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Heat Biologics
PR-M04-22-10Apr 18, 2022
Bioanalytics
Integrating and Automating Biomanufacturing and Bioanalytics
Scorpius BioManufacturing
PAO-02-22-R250-12Feb 11, 2022
Single-Use Technologies
Evaluating Single-Use Technologies for Biomanufacturing
Chris Barnett
Scorpius BioManufacturing
PAO-11-21-CL-08Nov 22, 2021